🟢 Opus Genetics is trading 5.58% up today after positive low-dose BIRD-1 results

Opus Genetics is trading at $6.05, up 5.58% after positive low-dose Cohort 1 results from the Phase 1/2 BIRD-1 trial.

• The stock is extending its September 9 rally.
• All five participants improved in at least one visual-function measure, while four showed structural retinal improvements.
• Favorable tolerability and a successful FDA Type C meeting support potential Phase 3 dosing in 2027, despite broader U.S. markets trading lower.